Search This Blog

Sunday, June 1, 2014

Amgen Highlights Phase 2 Results Of Vectibix® (panitumumab) Versus bevacizumab In Combination With FOLFOX In Patients With Wild-Type RAS (KRAS And NRAS) Metastatic Colorectal Cancer

Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.